ICARIA-MM: Second Interim Analysis of Phase III Study of Addition of Isatuximab to Pomalidomide and Low-Dose Dexamethasone in R/R Myeloma

June 4-8, 2021; Online at https://conferences.asco.org/am
Updated results from ICARIA-MM confirm significant PFS benefit and show improvement in time to next therapy with addition of isatuximab to pomalidomide/low-dose dexamethasone in relapsed/refractory myeloma.
Format: Microsoft PowerPoint (.ppt)
File Size: 311 KB
Released: June 9, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Related Content

CCO Conference Coverage of ASH 2021 with downloadable slides and experts’ commentaries of clinically relevant studies

John M. Burke, MD Amy E. DeZern, MD, MHS Shaji K. Kumar, MD Sagar Lonial, MD Peter Martin, MD Mark A. Schroeder, MD Sujit Sheth, MD B Douglas Smith B. Douglas Smith, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Released: December 8, 2021

Commentary on considerations affecting therapy recommendations for patients with myeloma in the evolving treatment landscape, from Clinical Care Options (CCO)

Brian G.M. Durie, MD
Program Director
Thomas G. Martin, MD Philippe Moreau, MD S. Vincent Rajkumar, MD Jesús F. San-Miguel, MD, PhD
Released: December 7, 2021

Commentary from Dr. Julie Vose on how to select therapy for patients with EBV-positive PTLD, from Clinical Care Options (CCO)

Julie M. Vose, MD, MBA Released: December 6, 2021

Interactive online tool with expert recommendations for assessing and managing adverse events associated with BTK inhibitors, from Clinical Care Options

Farrukh T. Awan, MD Christopher R. Flowers, MD, MS Nicole Lamanna, MD John P. Leonard, MD Julie M. Vose, MD, MBA Released: December 6, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.